LY4050784 + pembrolizumab + carboplatin + paclitaxel

This is a **combination regimen composed of LY4050784, pembrolizumab, carboplatin, and paclitaxel.** - **LY4050784** is an oral, potent, and selective small molecule inhibitor of SMARCA2 (BRM), developed as a first-in-class agent targeting chromatin remodeling in cancers with inactivating SMARCA4 (BRG1) alterations. Its mechanism is based on synthetic lethality: in SMARCA4-deficient cancers, cells become dependent on SMARCA2, so selective inhibition of SMARCA2 with LY4050784 can cause cancer cell death[1][2][3][4]. - **Pembrolizumab** is a humanized monoclonal antibody targeting PD-1, acting as an immune checkpoint inhibitor, enhancing T-cell–mediated antitumor immune response. - **Carboplatin** is a platinum-containing chemotherapy agent that creates DNA crosslinks, leading to DNA damage and cell death. - **Paclitaxel** is a microtubule-stabilizing chemotherapy agent that inhibits mitosis, resulting in cell cycle arrest and apoptosis. This specific four-drug combination is being studied in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and other solid tumors with SMARCA4 (BRG1) alterations in a Phase 1 clinical trial to assess safety, tolerability, and efficacy[2][4][5]. LY4050784 is being developed in partnership by Eli Lilly and Foghorn Therapeutics[1][2]. Pembrolizumab is developed and manufactured by Merck. Carboplatin and paclitaxel are generic drugs, formerly developed by Bristol Myers Squibb, but now manufactured by multiple companies.

Brand names

none for LY4050784none for carboplatinnone for paclitaxel

Other names

FHD-909 (LY4050784)BRM inhibitor (LY4050784)pembrolizumab (Keytruda)paclitaxel (Taxol)